2014
DOI: 10.1016/j.canlet.2014.07.009
|View full text |Cite
|
Sign up to set email alerts
|

Interplay between estrogen and retinoid signaling in breast cancer – Current and future perspectives

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
6
0

Year Published

2015
2015
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 11 publications
(6 citation statements)
references
References 79 publications
0
6
0
Order By: Relevance
“…It is important to emphasize that even though E7 induces high genomic instability, this mouse does not develop cancer but only a moderate squamous epithelial hyperplasia in the exocervix [31]. As was mentioned previously, the K14E7 transgenic mice only develops cervical cancer when they are chronically treated for 6 months with 17b-estradiol; interestingly, it was reported in breast cancer that the estrogen receptors (ERa and ERb), which are activated by 17b-estradiol repress RARB gene transcription [47]. Based on these findings, one might suggest that in K14E7 transgenic mouse, the increase of Rarb expression induced by the E7 oncoprotein is given in the absence of estrogen before the tumor develops.…”
Section: Discussionmentioning
confidence: 89%
“…It is important to emphasize that even though E7 induces high genomic instability, this mouse does not develop cancer but only a moderate squamous epithelial hyperplasia in the exocervix [31]. As was mentioned previously, the K14E7 transgenic mice only develops cervical cancer when they are chronically treated for 6 months with 17b-estradiol; interestingly, it was reported in breast cancer that the estrogen receptors (ERa and ERb), which are activated by 17b-estradiol repress RARB gene transcription [47]. Based on these findings, one might suggest that in K14E7 transgenic mouse, the increase of Rarb expression induced by the E7 oncoprotein is given in the absence of estrogen before the tumor develops.…”
Section: Discussionmentioning
confidence: 89%
“…Preclinical studies have shown that RA and its derivatives have significant anti-proliferative and pro-apoptotic effects in breast cancer. However, clinical trials in breast cancer patients have been disappointing; because of low efficacy, metabolic disorders, and drug resistance, especially in ER-negative breast cancer [ 2 ]. Metabolic disorders are key risk factors for breast cancer, and several clinical investigations have shown a significant association between metabolic syndrome and breast cancer in women [ 3 , 4 ].…”
Section: Introductionmentioning
confidence: 99%
“…Whether there is a connection between the decreased expression of Nkx6-1 and the risk of cancer remains to be established. The nuclear receptors (RARB and THRB) that are known to cooperate with ESR1 signalling 73 , 74 also harbours the binding motifs for ESR1 within differential peaks, suggesting the potential role for these receptors in mediating the CD effects. In summary, our data suggest that the interplay between POU5F1, ZFP57 and ESR1 network is important for transgenerational inheritance of epigenetic changes caused by endocrine disrupting chemicals (e.g., CD).…”
Section: Discussionmentioning
confidence: 99%